Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
SA Pharmacy, Women's and Children's Hospital, Adelaide, SA, Australia.
Drug Des Devel Ther. 2024 Mar 22;18:899-908. doi: 10.2147/DDDT.S444581. eCollection 2024.
Co-administering multiple intravenous (IV) agents via Y-connectors is a common practice in hospitalised and fasting surgical patients. However, there is a lack of reliable data confirming the physical compatibility of some combinations including IV oxycodone, a drug that is gaining increasing popularity in the perioperative period. Concern regarding physical drug incompatibilities precludes concurrent coadministration with other common drugs through a single lumen. This can result in the cessation of infusions to allow the administration of other medications, resulting in exacerbation of acute pain. This study aims to evaluate the physical compatibility of IV oxycodone with some commonly co-administered drugs and IV fluids.
Mixtures of oxycodone (1mg.mL) and the tested drugs and IV fluids were prepared in a ratio of 1:1. The mixtures were examined at 0 and 60 minutes from mixing and assessed using the European Conference Consensus Standards. This involved visual inspection (precipitation, turbidity, colour change, gas formation), spectrophotometry, and pH change. The tested drugs included ketamine, tramadol, clonidine, vancomycin, piperacillin/tazobactam, dexmedetomidine, cefotaxime, gentamicin, and paracetamol. In addition, the commonly used IV fluids tested included glucose 5% + sodium chloride 0.9% + 60 mmol potassium chloride, plasmalyte + dextrose 5%;plasmalyte + dextrose 5% + 55 mmol potassium chloride, plasmalyte + dextrose 5% + 55mmol potassium acetate, plasmalyte + dextrose 5% + 55mmol potassium dihydrogen phosphate, Hartmann's solution, Standard pediatric Total Parenteral Nutrition (TPN) 20/100 and TPN 25/150.
IV oxycodone (1 mg.mL) showed no visual changes; no spectrophotometric absorption variability at 350, 410, or 550nm; and no pH changes of >0.5 at 0 or 60 minutes with any of the tested drugs or fluids in the concentrations tested.
According to European Consensus Conference Standards, IV Oxycodone at 1 mg.mL is physically compatible in a ratio of 1:1 v/v with all investigated drugs and fluids tested for at least 60 minutes.
在住院和禁食手术患者中,通过 Y 型连接器同时输注多种静脉(IV)药物是一种常见做法。然而,缺乏可靠数据来证实某些组合的物理相容性,包括在围手术期越来越受欢迎的 IV 羟考酮药物。对物理药物不相容性的担忧排除了通过单个管腔同时给予其他常用药物。这可能导致停止输注以允许给予其他药物,从而导致急性疼痛加剧。本研究旨在评估 IV 羟考酮与一些常用共同给予的药物和 IV 液的物理相容性。
以 1:1 的比例制备 1mg/mL 的羟考酮与测试药物和 IV 液的混合物。混合后 0 分钟和 60 分钟时进行检查,并使用欧洲共识会议标准进行评估。这涉及目视检查(沉淀、混浊、颜色变化、气体形成)、分光光度法和 pH 值变化。测试药物包括氯胺酮、曲马多、可乐定、万古霉素、哌拉西林/他唑巴坦、右美托咪定、头孢噻肟、庆大霉素和对乙酰氨基酚。此外,还测试了常用的 IV 液,包括 5%葡萄糖+0.9%氯化钠+60mmol 氯化钾、血浆代用品+葡萄糖 5%;血浆代用品+葡萄糖 5%+55mmol 氯化钾、血浆代用品+葡萄糖 5%+55mmol 醋酸钾、血浆代用品+葡萄糖 5%+55mmol 磷酸二氢钾、哈特曼溶液、标准儿科全胃肠外营养(TPN)20/100 和 TPN 25/150。
IV 羟考酮(1mg/mL)无目视变化;在 350、410 或 550nm 处无分光光度吸收变化;在 0 分钟或 60 分钟时,在所测试的浓度下,与任何测试药物或液体的 pH 值变化均>0.5。
根据欧洲共识会议标准,1mg/mL 的 IV 羟考酮在至少 60 分钟内与所有测试的药物和液体在 1:1v/v 的比例下在物理上是相容的。